BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36819558)

  • 1. A novel human multiple myeloma cell line with a 1q21 gain genetic abnormality and CKS1B overexpression.
    He J; Yi K; Zhang Y; Zhang H; Hou J; Li R
    Ann Transl Med; 2023 Jan; 11(2):126. PubMed ID: 36819558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
    Chang H; Jiang N; Jiang H; Saha MN; Qi C; Xu W; Reece D
    Haematologica; 2010 Sep; 95(9):1542-7. PubMed ID: 20421271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
    Fonseca R; Van Wier SA; Chng WJ; Ketterling R; Lacy MQ; Dispenzieri A; Bergsagel PL; Rajkumar SV; Greipp PR; Litzow MR; Price-Troska T; Henderson KJ; Ahmann GJ; Gertz MA
    Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.
    Stella F; Pedrazzini E; Baialardo E; Fantl DB; Schutz N; Slavutsky I
    Blood Cells Mol Dis; 2014 Sep; 53(3):110-7. PubMed ID: 24973170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma.
    Ma ES; Wang CL; Wong AT; Choy G; Chan TL
    Mol Cytogenet; 2016; 9():63. PubMed ID: 27532015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma.
    Hanamura I
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
    Shaughnessy J
    Hematology; 2005; 10 Suppl 1():117-26. PubMed ID: 16188652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications.
    Bahmanyar M; Qi X; Chang H
    Leuk Res; 2013 Dec; 37(12):1726-8. PubMed ID: 24169086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
    Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
    Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.
    Chen H; Zhou N; Shi H; Yu W; Wu L; Zhou F
    Hematology; 2023 Dec; 28(1):2177979. PubMed ID: 36794720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
    An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
    Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.
    Minguela A; Vasco-Mogorrón MA; Campillo JA; Cabañas V; Remigia MJ; Berenguer M; García-Garay MC; Blanquer M; Cava C; Galian JA; Gimeno L; Soto-Ramírez MF; Martínez-Hernández MD; de la Rubia J; Teruel AI; Muro M; Periago A
    Am J Cancer Res; 2021; 11(9):4438-4454. PubMed ID: 34659897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.
    Chang H; Qi X; Trieu Y; Xu W; Reader JC; Ning Y; Reece D
    Br J Haematol; 2006 Nov; 135(4):486-91. PubMed ID: 16995883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients.
    You H; Jin S; Wu C; Wang Q; Yan S; Yao W; Shi X; Shang J; Yan L; Yao Y; Wang J; Wang P; Pan J; Wu D; Fu C
    Front Oncol; 2022; 12():938392. PubMed ID: 36276097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets.
    Burroughs Garcìa J; Eufemiese RA; Storti P; Sammarelli G; Craviotto L; Todaro G; Toscani D; Marchica V; Giuliani N
    Cells; 2021 Jun; 10(6):. PubMed ID: 34205916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of fluorescence in-situ hybridization technique in multiple myeloma].
    Zhao Y; Zheng D; Li J; Zhu WT
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):459-64. PubMed ID: 19830857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization.
    Hu Y; Chen W; Chen S; Huang Z
    Onco Targets Ther; 2016; 9():1145-9. PubMed ID: 27042105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
    Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
    J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
    Zhan F; Colla S; Wu X; Chen B; Stewart JP; Kuehl WM; Barlogie B; Shaughnessy JD
    Blood; 2007 Jun; 109(11):4995-5001. PubMed ID: 17303695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.